Goals in Focus: CBT for Motivational Negative Symptoms of Psychosis - a Randomized-controlled Feasibility Trial (GIF)

Goals in Focus: CBT for Motivational Negative Symptoms of Psychosis - a Randomized-controlled Feasibility Trial (GIF) - GiF

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00018083

Enrollment

Registered

2019-08-28

Start date

2019-09-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F20-F29

Interventions

Group 1: Experimental: Goals in Focus Therapy Goals in Focus (GiF) is a symptom-specific treatment program that targets motivational negative symptoms in patients with schizophrenia-spectrum disorder

Eligibility

Sex/Gender

All

Age

16 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: - ICD-10 diagnosis of a schizophrenia spectrum disorder (confirmed by the Structured Clinical Interview for DSM V Clinical Version - at least moderate motivational negative symptoms (i.e., scores = 3 (moderate) in two items or = 4 (moderately severe) in one item of the ‘motivation and pleasure factor’ of the Brief Negative Symptom Scale (BNSS) - sufficient skills in German language to participate in psychological therapy - capable to engage in weekly therapy sessions of 50-minutes - prioritize the reduction of negative symptoms as their current goal for treatment - capable to give informed consent to participate in the trial

Exclusion criteria

Exclusion criteria: Exclusion Criteria: - being at immediate and serious risk to self or others - co-morbid diagnosis of alcohol or substance use disorder - intake of Benzodiazepines for >2 days per week - receiving any other psychological treatment aiming to reduce motivational negative symptoms

Design outcomes

Primary

Measure	Time frame
1.Brief Negative Symptoms Scale (BNSS) - 'motivation and pleasure factor' score The primary outcome is defined as the change in motivational negative symptoms assessed with the 'motivation and pleasure factor' of the Brief Negative Symptoms Scale (BNSS). The BNSS is a 13-item semi-structured interview measuring negative symptoms on two factors, namely 'motivation and pleasure' and 'reduced expressivity'. The 'motivation and pleasure factor' includes seven items that measure the subscales of 'anhedonia', 'avolition', and 'asociality'. Symptoms are rated on a seven-point scale ranging from 0 "no impairment" to 6 "severe deficit". Time Frame: at baseline assessment and 6 months after baseline assessment	—

Measure

Time frame

1.Brief Negative Symptoms Scale (BNSS) - 'motivation and pleasure factor' score The primary outcome is defined as the change in motivational negative symptoms assessed with the 'motivation and pleasure factor' of the Brief Negative Symptoms Scale (BNSS). The BNSS is a 13-item semi-structured interview measuring negative symptoms on two factors, namely 'motivation and pleasure' and 'reduced expressivity'. The 'motivation and pleasure factor' includes seven items that measure the subscales of 'anhedonia', 'avolition', and 'asociality'. Symptoms are rated on a seven-point scale ranging from 0 "no impairment" to 6 "severe deficit". Time Frame: at baseline assessment and 6 months after baseline assessment

—

Secondary

Measure	Time frame
2. Brief Negative Symptoms Scale (BNSS) All five subscales of the BNSS (i.e., avolition, asociality, anhedonia, blunted affect, and alogia, will be examined as secondary outcomes. [Time Frame: at baseline assessment and 6 months after baseline assessment] 3. Role Functioning Scale (RFS) Psychosocial Functioning will be assessed using the RFS - a semi-structured intereview on four domains of functioning. [Time Frame: at baseline assessment and 6 months after baseline assessment] 4. Global Assessment of Functioning (GAF) The GAF will be used as an observer-rating of changes in psychosocial functioning. Functioning is rated on a single scale. [Time Frame: at baseline assessment and 6 months after baseline assessment] 5. Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) The WEMBS is a self-report questionnaire and consists of fourteen statements on well-being during the previous two weeks. [Time Frame: at baseline assessment and 6 months after baseline assessment] 6. Calgary Depression Rating Scale for Schizophrenia (CDSS) The CDSS is a semi-structured interview, which was developed to measure depressive symptoms in patients with schizophrenia. [Time Frame: at baseline assessment and 6 months after baseline assessment] 7. Goal-pursuit within daily-life Daily-life goal-pursuit will be assessed using the Experience Sampling Method (ESM). Participants will be prompted two times per day (10am and 10pm) over the course of one week via the MovisensXSapplication (Movisens GmbH) installed on a smartphone device. At the beginning of the ESM assessment, the participants' self-efficacy will be assessed with the Generalized Self-Efficacy Scale (GSE) Each of the following '10am prompts' will ask the participants to nominate a goal that they would like to achieve during the respective day and to rate characteristics of this goal (e.g., goal-commitment, goal-importance, goal-difficulty etc.). At the '10pm prompts', participants will be asked to indicate to what extent they	—

Measure

Time frame

2. Brief Negative Symptoms Scale (BNSS) All five subscales of the BNSS (i.e., avolition, asociality, anhedonia, blunted affect, and alogia, will be examined as secondary outcomes. [Time Frame: at baseline assessment and 6 months after baseline assessment] 3. Role Functioning Scale (RFS) Psychosocial Functioning will be assessed using the RFS - a semi-structured intereview on four domains of functioning. [Time Frame: at baseline assessment and 6 months after baseline assessment] 4. Global Assessment of Functioning (GAF) The GAF will be used as an observer-rating of changes in psychosocial functioning. Functioning is rated on a single scale. [Time Frame: at baseline assessment and 6 months after baseline assessment] 5. Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) The WEMBS is a self-report questionnaire and consists of fourteen statements on well-being during the previous two weeks. [Time Frame: at baseline assessment and 6 months after baseline assessment] 6. Calgary Depression Rating Scale for Schizophrenia (CDSS) The CDSS is a semi-structured interview, which was developed to measure depressive symptoms in patients with schizophrenia. [Time Frame: at baseline assessment and 6 months after baseline assessment] 7. Goal-pursuit within daily-life Daily-life goal-pursuit will be assessed using the Experience Sampling Method (ESM). Participants will be prompted two times per day (10am and 10pm) over the course of one week via the MovisensXSapplication (Movisens GmbH) installed on a smartphone device. At the beginning of the ESM assessment, the participants' self-efficacy will be assessed with the Generalized Self-Efficacy Scale (GSE) Each of the following '10am prompts' will ask the participants to nominate a goal that they would like to achieve during the respective day and to rate characteristics of this goal (e.g., goal-commitment, goal-importance, goal-difficulty etc.). At the '10pm prompts', participants will be asked to indicate to what extent they

—

Countries

Germany

Contacts

Public ContactMatthias Pillny

Universität Hamburg, Klinische Psychologie und Psychotherapie

matthias.pillny@uni-hamburg.de+4940428384023

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 11, 2026